Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- Registration Number
- NCT01596400
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Brief Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
-
13 to 17 years of age inclusive at screening.
-
Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
-
Written patient assent (as appropriate).
-
Confirmed malignancy.
-
Scheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.
-
Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.
- The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.
-
Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
-
Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
-
Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
-
Patients scheduled to have routine surgery during the study duration.
-
Patients with a life expectancy of < 6 months.
-
Scarring or significant skin disease on both upper arms.
-
Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
-
Patients who are known or thought to be sexually active must use effective birth control.**
-
Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
-
Any conditions associated with non-compliance.
- Effective birth control includes absolute abstinence, or double barrier birth control methods, i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sancuso Arm granisetron transdermal system - IV Granisetron Arm Granisetron IV IV
- Primary Outcome Measures
Name Time Method Plasma concentration Up to 7 days Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.
- Secondary Outcome Measures
Name Time Method Chang is Safety from baseline Up to 7 days Safety: based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms (ECGs)
Trial Locations
- Locations (12)
David Geffen School of Medicine at UCLA
🇺🇸Los Angeles, California, United States
Children's Hospital of Orange County
🇺🇸Orange, California, United States
Nemours Children's Clinic
🇺🇸Jacksonville, Florida, United States
Penn State Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
UTSW/Childrens Medical Center
🇺🇸Dallas, Texas, United States
Providence Sacred Heart Medical Center and Children's Hospital
🇺🇸Spokane, Washington, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Madigan Army Medical Center
🇺🇸Tacoma, Washington, United States
Children's Hospital Colorado, Center for Cancer and Blood Disorders
🇺🇸Aurora, Colorado, United States
University of Florida
🇺🇸Gainesville, Florida, United States
University of South Florida
🇺🇸Tampa, Florida, United States